Arcus Biosciences (RCUS) Change in Accured Expenses (2017 - 2022)

Arcus Biosciences' Change in Accured Expenses history runs 6 years deep, the most recent figure standing at $6.1 million for Q3 2022.

• In Q3 2022, Change in Accured Expenses rose 23.81% year-over-year to $6.1 million; the TTM figure through Sep 2022 stood at $926000.0 (down 88.14% YoY), while the FY2021 annual figure was $10.1 million, up 120.73% from the prior year.
• Change in Accured Expenses for Q3 2022 stood at $6.1 million, up from -$1.8 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $6.1 million in Q3 2022, with the low at -$8.5 million in Q1 2022.
• The 5-year median for Change in Accured Expenses is $1.2 million (2020), against an average of $659578.9.
• The sharpest annual moves came in 2018 and 2020: Change in Accured Expenses slumped 1282.32% in 2018, then surged 18060.0% in 2020.
• Arcus Biosciences' Change in Accured Expenses stood at -$2.3 million in 2018, then surged by 100.66% to $15000.0 in 2019, then soared by 18060.0% to $2.7 million in 2020, then jumped by 85.61% to $5.1 million in 2021, then advanced by 20.45% to $6.1 million in 2022.
• Business Quant data shows RCUS's Change in Accured Expenses at $6.1 million in Q3 2022, -$1.8 million in Q2 2022, and -$8.5 million in Q1 2022.